8-K: AVITA Medical Revises Q1 Revenue Expectations, Cites Slower Account Conversions

AVITA Medical has lowered its expected first-quarter 2024 revenue due to a slower-than-anticipated conversion rate of new accounts, while reaffirming its full-year revenue guidance at the lower end of the previously provided range.

Summary

• AVITA Medical has updated its expected commercial revenue for the first quarter of 2024 to be between $11.0 million and $11.3 million.
• This is below the previously provided guidance of $14.8 million to $15.6 million.
• The company attributes this revision to a slower-than-expected conversion rate of new accounts for their expanded label of full-thickness skin defects.
• Despite the slower conversion rate, AVITA Medical has added 73 new accounts since the launch of the expanded label in June 2023, including 22 in the first quarter of 2024.
• There are also 71 submissions in the evaluation or decision stage of the value analysis committee (VAC) process as of March 31, 2024.
• The company had projected an approval rate of 15 new accounts per month, expecting a total of 135 new accounts by March 31, 2024.
• AVITA Medical reaffirms its full-year 2024 revenue guidance at the lower end of the previously provided range of $78.5 million to $84.5 million.
• The company plans to report its first-quarter 2024 financial results on May 13, 2024, and will host a conference call to discuss the results.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant downward revision in Q1 revenue guidance, although the company maintains a positive outlook for the full year. The slower account conversion rate is a concern, but the company's efforts to address this and the upcoming product launches provide some optimism.

Positives

• AVITA Medical has added 73 new accounts since the launch of the expanded label in June 2023, indicating continued market interest.
• The company has a robust pipeline with 71 submissions in the VAC process, suggesting potential for future growth.
• The launch of PermeaDerm in March and the upcoming launch of RECELL GO are expected to contribute to revenue growth.
• AVITA Medical remains committed to meeting the lower end of its full-year revenue guidance.

Negatives

• The first quarter revenue is expected to be significantly lower than previously guided, with a range of $11.0 million to $11.3 million compared to $14.8 million to $15.6 million.
• The conversion rate of new accounts for the expanded label has been slower than expected.
• The company did not meet its target of 135 new accounts by March 31, 2024, with only 73 new accounts added since June 2023.

Risks

• The slower-than-expected conversion rate of new accounts could continue to impact revenue growth.
• The complexity of closing new accounts for a product with multiple indications may pose ongoing challenges.
• The company's ability to meet the lower end of its full-year revenue guidance depends on the success of new product launches and improved account conversion rates.
• There is a risk that the 71 submissions in the VAC process may not convert to new accounts at the anticipated rate.

Future Outlook

AVITA Medical expects to meet the lower end of its previously provided full-year 2024 revenue guidance of $78.5 million to $84.5 million, driven by new product launches and improved account conversion rates.

Management Comments

• Jim Corbett, Chief Executive Officer of AVITA Medical, stated that they are intensifying efforts to drive growth in light of the challenges encountered in the first quarter of 2024.
• He also mentioned that while the account conversion rate impacted quarterly revenue, they remain optimistic for the full year.
• He believes that the recent launch of PermeaDerm and the upcoming launch of RECELL GO, along with a deeper understanding of the VAC processes, will help them meet the lower end of their annual revenue guidance.

Industry Context

This announcement reflects the challenges faced by medical device companies in converting new accounts, particularly for products with multiple indications. The slower-than-expected conversion rate highlights the complexities of the healthcare procurement process and the need for effective sales strategies.

Comparison to Industry Standards

• The revised revenue guidance suggests that AVITA Medical is facing challenges in scaling its sales efforts, which is not uncommon for companies in the medical device sector.
• Companies like Integra LifeSciences and Smith & Nephew, which also operate in the wound care market, have faced similar challenges in new product adoption and account conversions.
• The delay in account conversions is a common issue in the medical device industry, where hospital value analysis committees (VACs) can have lengthy and complex approval processes.
• The company's reliance on new product launches to meet its annual revenue guidance is a common strategy, but it also introduces execution risk.

Stakeholder Impact

• Shareholders may react negatively to the reduced Q1 revenue guidance.
• Employees may face increased pressure to improve sales performance.
• Customers may experience delays in the adoption of the company's products.
• Suppliers may be affected by changes in the company's sales forecasts.

Next Steps

• AVITA Medical plans to report its financial results for the first quarter 2024 on May 13, 2024.
• A conference call and webcast are scheduled for May 14, 2024, to discuss the results in further detail.
• The company will focus on intensifying efforts to drive growth and improve account conversion rates.
• The company will continue to launch new products such as RECELL GO.

Key Dates

Keywords

AVITA Medical, Revenue, Guidance, Wound Care, Regenerative Medicine, RECELL System, PermeaDerm, Skin Restoration, Account Conversion, VAC Process